Protocol Ledger

NCT03591874 · Phase III · TERMINATED

Study of Brimonidine Tartrate Nanoemulsion Eye Drops in Patients With Ocular Graft-vs-Host Disease

Interventional Phase III clinical trial protocol NCT03591874 sponsored by Ocugen in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-12-23 Enrollment: 59 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03591874
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)59 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03591874
Protocol FieldVerified Registry Value
NCT IdentifierNCT03591874
Consolidated Lead SponsorOcugen
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment59 participants (ACTUAL)
Registered Start Date2018-12-23
WhyStopped ClassificationUnspecified

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI